Patient-friendly peptide education
General peptide therapy, clinics, safety, brands and long-tail topics.
Recently published
Approval is reportedly the first to allow dosing every two years. FDA approved Novartis’ Reclast(r) as the first two-yearly treatment for the prevention of postmenopausal osteoporosis. The agency based its app…
Read guide →Whereas we mostly tend to think of arthritis as an old person’s disease, there is a form of it that affects children—and those kids now have a reason to jump for joy. The FDA just approved Novartis’ Ilaris® (c…
Read guide →Metal Peptide Complex Metal Peptide Complex and the Importance of Individual System Variability Historical patterns in peptide research demonstrate how innovation in one area often stimulates progress in relat…
Read guide →The European Commission approved the Vertex Pharmaceuticals drug Kalydeco™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibro…
Read guide →Grc Peptides 2025 Grc Peptides 2025 Demystified:Multi-Dimensional Interpretation Of Basic Traits Comprehensive market analysis reveals accelerating adoption of synthetic peptides across pharmaceutical and cosm…
Read guide →Wolverine Peptide Frequency Deconstructing Wolverine Peptide Frequency:Molecular Behavior in Serum-Free Media A deeper understanding of side-chain protection mechanisms supports safer handling of peptide molec…
Read guide →The FDA has issued final guidance for biopharmas seeking to incorporate what the agency deems “promising emerging and novel technologies” in their drug manufacturing processes. The final guidance, titled “Adva…
Read guide →Sponsored content brought to you by Even with standard methods of care, 55% of the 2 million people diagnosed with cancer this year will unfortunately pass. With this devastating statistic in mind, researchers…
Read guide →Peptide Stock Photos What's New with Peptide Stock Photos: My Take on Scalable Peptide Production Global market interest in stabilized peptide formulations has expanded across several pharmaceutical and cosmet…
Read guide →$900,000 over two years will go toward enhancing the peptide manufacturing and delivery technologies. Unigene Laboratories received a $900,000 funding to advance it’s discovery program related to therapeutic p…
Read guide →Cells That Respond To Peptide Hormones Usually Do So Through Mapping Cells That Respond To Peptide Hormones Usually Do So Through:Signaling Logic in Skin Barrier Models Data-driven experimental design accelera…
Read guide →Collaboration will focus on tau-related AD and will leverage Bayer’s imaging tools. TauRx Pharmaceuticals and Bayer Schering Pharma (BSP) are allying to develop diagnostics for Alzheimer disease (AD) treatment…
Read guide →Agreement initially covers BI’s registrational linagliptin, an SGLT-2 blocker, and two Lilly basal insulin analogues. Lilly is paying Boehringer Ingelheim (BI) €300 million (about $402 million) up front to sea…
Read guide →Dual-mechanism oral small molecule MBX-2982 acts as GPR119 agonist. Sanofi-Aventis negotiated a global license and development agreement with Metabolex centered on small molecule type 2 diabetes therapies that…
Read guide →Dyax could receive over $100 million in development and sales milestones. Sigma-Tau SpA is paying Dyax $2.5 million in cash and will make a $2.5 million equity investment in the firm as part of a partnership t…
Read guide →Firm also gains an option to license Vaxisome for use with its pipeline vaccines. NasVax entered into a joint research and option for license agreement with Novartis Vaccines and Diagnostics to investigate the…
Read guide →Firm says partnering vaccines will allow it to concentrate on CLIPS-based mAbs. Pepscan is to receive a minority stake in Immunovo as part of the companies’ agreement to partner on development of Pepscan’s the…
Read guide →Alliance targets 11beta-HSD-1 for the treatment of metabolic syndrome disorders. Vitae Pharmaceuticals received a $14 million milestone payment from Boehringer Ingelheim with the initiation of a Phase I trial.…
Read guide →Patient recruitment for trial with expanded neural stem cell product will begin in April. Stem cell therapeutics company ReNeuron raised about £4.7 million (almost $7.3 million) before expenses in a fundraisin…
Read guide →PD01 is designed to trigger antibodies that bind to and clear alpha-synuclein from the brain. AFFiRiS was awarded $1.5 million from the Michael J. Fox Foundation (MJFF) to support a Phase I study with its Park…
Read guide →Browse by subject
Each topic opens a crawlable collection of related articles and resources.